CMPX Stock Price, Compass Therapeutics Inc Quote, Chart

Market Summary

USD1.600.00

Delayedas of 17 May 2024, 11:56 am

0.00%

CMPX Stock Price

View Fullscreen

CMPX RSI Chart

CMPX Valuation

Market Cap

220.1M

Price/Earnings (Trailing)

-4.84

EV/EBITDA

-4.39

Price/Free Cashflow

-5.2

MarketCap/EBT

-4.84

CMPX Price/Earnings (Trailing)

CMPX Profitability

Return on Equity

-28.93%

Return on Assets

-28.2%

Free Cashflow Yield

-19.22%

CMPX Fundamentals

CMPX Earnings

Earnings (TTM)

-45.4M

Earnings Growth (Yr)

-37.64%

Earnings Growth (Qtr)

19.59%

Breaking Down CMPX Revenue

52 Week Range

1.593.62

(Low)(High)

Last 30 days

1.3%

Last 90 days

-15.9%

Trailing 12 Months

-50.9%

How does CMPX drawdown profile look like?

CMPX Financial Health

Current Ratio

40.74

CMPX Investor Care

Shares Dilution (1Y)

8.76%

Tracking the Latest Insider Buys and Sells of Compass Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 08, 2024	schuetz thomas j.	sold (taxes)	-64,933	1.45	-44,782	president
Feb 08, 2024	bisker-leib vered	sold (taxes)	-71,337	1.45	-49,198	chief executive officer
Jan 09, 2024	schuetz thomas j.	acquired	1,230,380	1.93	637,500	president of r&d
Jan 09, 2024	bisker-leib vered	acquired	3,383,530	1.93	1,753,120	chief executive officer
Nov 17, 2023	bisker-leib vered	sold (taxes)	-96,622	1.5	-64,415	chief operating officer
Nov 17, 2023	schuetz thomas j.	sold (taxes)	-66,037	1.5	-44,025	chief executive officer
Mar 10, 2023	schuetz thomas j.	bought	33,700	3.37	10,000	chief executive officer
Feb 27, 2023	schuetz thomas j.	bought	79,600	3.98	20,000	chief executive officer
Feb 15, 2023	schuetz thomas j.	bought	77,200	3.86	20,000	chief executive officer
Feb 08, 2023	bisker-leib vered	acquired	-	-	400,000	chief operating officer

Which funds bought or sold CMPX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Blue Owl Capital Holdings LP	unchanged	-	1,188,480	5,602,830	1.12%
May 15, 2024	Cormorant Asset Management, LP	new	-	11,009,400	11,009,400	0.48%
May 15, 2024	Rock Springs Capital Management LP	unchanged	-	2,315,790	10,917,300	0.28%
May 15, 2024	Opaleye Management Inc.	new	-	6,276,600	6,276,600	1.44%
May 15, 2024	Squarepoint Ops LLC	reduced	-42.73	-37,795	100,608	-%
May 15, 2024	MPM BIOIMPACT LLC	new	-	3,903,380	3,903,380	0.63%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-50.37	-52,814	89,920	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	3.00	11,000	48,000	-%
May 15, 2024	Ally Bridge Group (NY) LLC	sold off	-100	-1,302,020	-	-%
May 15, 2024	HSBC HOLDINGS PLC	reduced	-67.41	-27,154	20,742	-%

Are Funds Buying or Selling CMPX?

Are funds buying CMPX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CMPX

No. of Funds

Unveiling Compass Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 22, 2024	orbimed advisors llc	13.7%	18,791,422	SC 13D/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	7.75%	9,880,000	SC 13G/A
Feb 01, 2024	janus henderson group plc	6.0%	7,647,740	SC 13G
Nov 27, 2023	adage capital partners gp, l.l.c.	5.66%	7,211,800	SC 13G
Feb 14, 2023	rock springs capital management lp	4.22%	5,333,188	SC 13G/A
Feb 13, 2023	foresite capital fund v, l.p.	3.5%	0	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Nov 14, 2022	commander aggregator, lp	6.17%	0	SC 13D
Nov 10, 2022	orbimed advisors llc	14.9%	18,791,422	SC 13D/A

Recent SEC filings of Compass Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 25, 2024	8-K	Current Report
Mar 22, 2024	SC 13D/A	13D - Major Acquisition
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 11, 2024	4	Insider Trading

Peers (Alternatives to Compass Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Compass Therapeutics Inc News

Latest updates

Compass Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q2	2019Q1	2018Q4
Assets	2.7%	161	157	170	179	188	200	128	140	147	154	35.00	41.00	48.00	52.00	61.00	70.00	50.00	30.00	42.00	53.00	65.00
Current Assets	3.1%	159	154	167	175	184	195	123	135	140	147	29.00	35.00	42.00	50.00	58.00	67.00	0.00	26.00	0.00	0.00	59.00
Cash Equivalents	-2.2%	24.00	24.00	30.00	19.00	27.00	35.00	16.00	26.00	136	145	26.00	31.00	40.00	47.00	56.00	65.00	0.00	25.00	38.00	0.00	58.00
Net PPE	-17.1%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00	3.00	-	4.00	-	-	5.00
Liabilities	-51.0%	4.00	8.00	10.00	11.00	13.00	18.00	12.00	13.00	12.00	14.00	11.00	12.00	15.00	12.00	13.00	17.00	18.00	19.00	19.00	19.00	20.00
Current Liabilities	-50.1%	4.00	8.00	9.00	10.00	11.00	16.00	10.00	11.00	9.00	11.00	8.00	8.00	11.00	10.00	10.00	12.00	0.00	10.00	0.00	0.00	8.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	4.00	6.00	-	9.00	-	-	11.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	4.00	6.00	7.00	7.00	7.00	7.00	-	6.00	-	-	4.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	4.00	6.00	-	9.00	-	-	11.00
Shareholder's Equity	5.7%	157	149	160	168	175	182	116	127	134	140	24.00	29.00	33.00	40.00	47.00	53.00	-	11.00	-	-	-
Retained Earnings	-3.4%	-326	-315	-301	-291	-280	-272	-261	-249	-240	-233	-220	-214	-158	-151	-143	-133	-0.11	-121	-0.08	-0.07	-87.16
Additional Paid-In Capital	4.2%	483	464	462	461	456	455	378	377	375	374	244	244	192	191	190	187	-	3.00	-	-	-
Shares Outstanding	7.8%	138	128	127	127	126	126	101	101	101	101	62.00	52.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	283	-	-	-	184	-	-	-	180	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-12.4%	-13,888	-12,354	-5,922	-10,113	-12,229	-10,641	-10,942	-4,600	-7,942	-4,665	-3,457	-5,939	-5,605	-6,573	-7,169	-5,300	-7,761	-2,799	-6,704	-	-9.81
Share Based Compensation	25.2%	2,003	1,600	1,625	1,628	1,267	1,025	1,287	1,444	1,574	1,186	987	908	948	1,050	2,536	183	247	226	249	-	-
Cashflow From Investing	-164.9%	-4,099	6,314	17,049	-667	4,269	-46,646	1,180	-105,541	-193	-776	-367	-614	-13.00	6.00	-7.00	51.00	-12.00	-185	-27.00	-	-
Cashflow From Financing	11133.5%	17,433	-158	21.00	3,031	41.00	75,752	5.00	-	-	124,236	-1,875	-1,875	-1,875	-1,875	-2,677	-	10.00	8.00	-	-	10.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CMPX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expense [Member]
Research and development	$ 9,522	$ 6,638
General and administrative	3,248	3,073
Total operating expenses	12,770	9,711
Loss from operations	(12,770)	(9,711)
Other income	1,983	1,874
Loss before income tax expense	(10,787)	(7,837)
Income tax expense	0	0
Net loss	$ (10,787)	$ (7,837)
Net loss per share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.06)
Basic and diluted weighted average shares outstanding (in shares)	136,608	126,375
Other comprehensive loss:
Net loss	$ (10,787)	$ (7,837)
Unrealized (loss) gain on marketable securities	(127)	156
Comprehensive loss	$ (10,914)	$ (7,681)

CMPX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 23,674	$ 24,228
Marketable securities	132,581	128,233
Prepaid expenses and other current assets	2,356	1,420
Total current assets	158,611	153,881
Property and equipment, net	744	898
Operating lease, right-of-use ("ROU") asset	1,467	1,776
Other assets	320	320
Total assets	161,142	156,875
Current liabilities:
Accounts payable	854	4,090
Accrued expenses	1,815	2,514
Operating lease obligations, current portion	1,224	1,197
Total current liabilities	3,893	7,801
Operating lease obligations, long-term portion	189	536
Total liabilities	4,082	8,337
Commitments and Contingencies
Stockholders' equity:
Common stock, $0.0001 par value: 300,000 shares authorized; 137,589 and 127,668 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	14	13
Additional paid-in-capital	483,231	463,796
Accumulated other comprehensive (loss) income	(90)	37
Accumulated deficit	(326,095)	(315,308)
Total stockholders' equity	157,060	148,538
Total liabilities and stockholders' equity	$ 161,142	$ 156,875

About Compass Therapeutics Inc

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
WEBSITE	compasstherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	26

Compass Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Compass Therapeutics Inc? What does CMPX stand for in stocks?

CMPX is the stock ticker symbol of Compass Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Compass Therapeutics Inc (CMPX)?

As of Thu May 16 2024, market cap of Compass Therapeutics Inc is 220.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CMPX stock?

You can check CMPX's fair value in chart for subscribers.

What is the fair value of CMPX stock?

You can check CMPX's fair value in chart for subscribers. The fair value of Compass Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Compass Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CMPX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Compass Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CMPX is over valued or under valued. Whether Compass Therapeutics Inc is cheap or expensive depends on the assumptions which impact Compass Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CMPX.